HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model.
|
23776583 |
2013 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
|
27564114 |
2016 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors in HER2-positive breast cancer.
|
28325261 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we performed a meta-analysis of randomized clinical trials (RCTs) to better define the benefit and the risk of CDK4/6 inhibitors plus ET for endocrine-sensitive or endocrine-resistant population in metastatic HR+/HER2- breast cancer.
|
30054831 |
2018 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focuses on the recent reports of the essential role of PI3K/Akt/mTOR and CDK4/6/RB pathways in ER+ HER2- breast cancer.
|
29086897 |
2018 |
HER2-positive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Managing endocrine resistance and resistance to endocrine therapy for ER+ HER2- breast cancer with the CDK 4/6 inhibitors in the metastatic setting.
|
31151842 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we review the published literature with regard to the rationale for CDK4/6-directed therapies in HER2+ BC and discuss ongoing clinical research and new challenges in the field.
|
31832106 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer.
|
31444334 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nowadays, three selective CDK4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) are approved by Federal Drug Administration and the European Medicines Agency for the treatment of advanced and metastatic HR+/HER2- breast cancer.
|
31777590 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical studies have demonstrated that CDK4/6 inhibitors can resensitize resistant HER2-positive breast cancer to anti-HER2 therapies.
|
31235441 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
|
30677445 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three CDK4/6 inhibitors, palbociclib (PAL), ribociclib (RIB), and abemaciclib, when combined with letrozole (LET), have been approved as first-line therapy for postmenopausal women with metastatic HR+, HER2- breast cancer.
|
30847728 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> We reviewed clinical trials investigating the efficacy of CDK4/6 inhibitors for advanced or metastatic HR+/HER2- breast cancer.
|
31695840 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data underscore the importance of CDK4/6 signaling in HR+/HER2‒ breast cancer and suggest that the interplay between steroid hormone and peptide growth factor signaling could drive dependence on CDK4/6 signaling.(Pfizer; NCT01740427).
|
31527167 |
2020 |